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aricella is a common infectious disease that typi-
cally occurs in childhood. It is caused by the
varicella-zoster (VZ) virus, a DNA herpesvirus that
is transmitted by respiratory droplets or direct con-
tact. Varicella is one of the most highly contagious
of all viral infections. Approximately 80-90% of sus-
ceptible individuals become infected after exposure
to an affected household member.
In healthy children, varicella usually does not
cause serious complications. However, immuno-
compromised children and otherwise healthy adults
are at increased risk for life-threatening complica-
tions of varicella such as pneumonia, encephalitis,
and disseminated infection. Although <10% of all
cases of varicella occur in adults, this age group
accounts for 25-30% of all varicella-related mortal-
ity. In addition, when pregnant women contract
varicella within the first 20 weeks of gestation, up
to 2% of their neonates have evidence of varicella
embryopathy.
Following a primary varicella infection, the VZ
virus may remain in a latent state for many years.
Under certain conditions, such as stress or immuno-
suppression, the infection may be reactivated as
herpes zoster. Although usually less severe than
varicella, herpes zoster may also cause serious com-
plications in some patients, particularly those with
immunodeficiency disorders.
Because of the potentially serious sequelae of
varicella in select groups of patients, researchers
and clinicians have long been interested in the de-
velopment of a vaccine to prevent the primary infec-
tion. In the latter part of 1995, the new varicella
vaccine (Varivax(R), Merck & Co., West Point, PA)
finally was approved by the U.S. Food and Drug
Administration for commercial marketing. The pur-
pose of this article is to review the pharmacology,
toxicity profile, clinical application, and cost of this
important new immunobiologic agent.
PHARMACOLOGY
The varicella vaccine was originally developed by
Takahashi et al. in 1974. 1The Oka/Merck strain
used in the vaccine is attenuated by passage in
human and embryonic guinea-pig cell cultures. The
vaccine activates both the humoral and cell-medi-
ated immune systems.
Children with leukemia were one of the original
target groups for the vaccine. After investigational
trials in normal children and adults, the vaccine was
administered to leukemic children who were no
longer receiving chemotherapy and, subsequently,
to children who had been in remission for year
but still required maintenance chemotherapy. In
these subjects, the vaccine has been highly immu-
nogenic, producing seroconversion in 90% and 97%
of patients after 1 and 2 doses, respectively. ’4 In
healthy children, 1-12 years old, a single dose of
vaccine results in seroconversion in approximately
97%. In healthy adolescents and adults, the rate of
seroconversion is approximately 80% after dose
and 90-95% after 2 doses. 1’4’5
Several investigators have demonstrated that im-
munity following vaccination is long lasting. Asano
et al. evaluated 25 Japanese children who received
one of the earliest vaccines prepared from the Oka
strain and found persistent antibody titers and cellu-
lar immune responses 20 years after vaccination.
Watson and colleagues followed 214 American chil-
dren for 6 years after vaccination and documented
persistent antibody in 95%. Moreover, 94% had evi-
dence of VZ-specific lymphocyte proliferation, in-
dicating appropriate activation of cell-mediated im-
munity in response to the varicella virus. Ninety-
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one percent of children had persistence of both hu-
moral and cell-mediated immunity. In a subsequent
investigation, Gershon et al. followed 40 adults for
7-13 years after vaccination and noted persistent
antibody in 82%.
The varicella vaccine is highly effective, but not
perfectly protective, in preventing natural infection.
In children with leukemia, the vaccine has reduced
the rate of transmission ofchickenpox from 80-90%
to 15-20%. 1’4 In addition, leukemic children who
develop varicella despite immunization have much
milder infections than would be anticipated with
natural infection. In normal children, the protective
efficacy of the vaccine is even higher. Weibel et
al. conducted a double-blind, placebo-controlled
trial of the vaccine in 956 children between ages
and 14 years. None ofthe 468 children who received
the vaccine developed varicella during the 9-month
period ofobservation after vaccination. Thirty-eight
of the 446 placebo recipients became infected
(P < 10-9). In adolescents and adults, the protective
efficacy of the vaccine is approximately 70-75%. 1’4
ADVERSE EFFECTS
The frequency of serious adverse effects following
the administration of the varicella vaccine is rela-
tively low. Approximately 10-15% of vaccinees ex-
perience fever, 5-10% develop reactions at the site
of injection, and 3-5% develop maculopapular or
vesicular eruptions. Fewer than 1% ofvaccine recip-
ients have fatigue, cough, vomiting, diarrhea, head-
ache, malaise, lymphadenopathy, arthralgias, pruri-
tus, or febrile seizures. Adolescents and adults are
more likely to have side effects than children aged
1-12 years. Vaccine recipients should be cautioned
against taking salicylates for control of the above
reactions because of the possibility of developing
Reye’s syndrome. 1,4,9
Recipients of the varicella vaccine, particularly
leukemic children, who develop skin rashes may
transmit the virus to susceptible close contacts.1
The frequency of transmission is approximately
10%, which is much lower than the transmission
rate with natural viral infection. Patients who do
not develop rashes apparently do not transmit the
virus to susceptible contacts. Vaccine recipients,
even those who are immunocompromised, do not
have an increased frequency of herpes zoster com-
pared with individuals who are infected with the
wild virtls. 1,4,9 In fact, the subsequent incidence of
herpes zoster in vaccinees may be decreased.1
CLINICAL APPLICATION
The varicella vaccine is indicated for all susceptible,
immunocompetent individuals older than year.
Prior to the administration of the vaccine, the pa-
tient’s immune status should be verified by a clearly
documented medical history or a confirmatory VZ
serology. A child between ages and 12 years
should receive one 0.5 ml subcutaneous dose of the
vaccine. An adolescent or adult requires 2 vaccina-
tions, 4-8 weeks apart. The vaccine can be given
simultaneously with the measles-mumps-rubella
(MMR) vaccine, provided that separate syringes
and injection sites are used. 8,9
Approximately 6-8 weeks after vaccination, a se-
rologic test should be performed to document sero-
conversion. A child between ages 1 and 12 years
who fails to seroconvert after a single injection may
subsequently respond to a second vaccination. Indi-
viduals >12 years of age who do not seroconvert
after 2 doses should be advised that they remain
susceptible to natural varicella infection.
As noted previously, the original target group for
the varicella vaccine was children with leukemia.
Even in this population, the vaccine has been highly
immunogenic and remarkably safe. Although im-
munodeficienc is listed as a contraindication to
use of the vaccine, vaccination still may be consid-
ered in immunocompromised patients under care-
fully designed treatment protocols.
COST
The wholesale cost of the varicella vaccine is ap-
proximately $40 per dose. The vaccine must be
stored in a freezer and then reconstituted and ad-
ministered within 30 min of thawing. Accordingly,
the actual charge to the patient for the vaccine may
be slightly above $40 because of the added costs
of preparation and administration.
CONCLUSIONS
The varicella vaccine is a live attenuated vaccine
that is approximately 70-80% effective in pre-
venting, or attenuating, the course of a natural vari-
celia infection. A child between ages and 12 years
should receive subcutaneous dose of the vaccine.
An adolescent or adult requires 2 doses, adminis-
tered 4-8 weeks apart. The principal adverse effects
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associated with the administration of the vaccine
are pain and tenderness at the injection site and a
sparse, maculopapular or vesicular rash. The vari-
cella vaccine should not be given to pregnant
women or to patients who have received systemic
corticosteroids within the month prior to vaccina-
tion. It also should not be routinely administered
to immunodeficient patients except under a strictly
supervised research protocol.
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